semaglutide cease and desist The Food Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine's abilities and benefits to patients. In Out of Shortage, Into Controversy:

Blockbuster weight loss drugs can help treat ailments as disparate as addiction, blood clotting, and dementia but they also come with risks that might give some patients pause, a landmark new study has found

Anything that helps patients return to normal breathing patterns more quickly reduces this risk

Key results: 12 mg dose: Average weight loss of 24.2 percent of body weight 8 mg dose: Average weight loss of 22.8 percent 4 mg dose: Average weight loss of 17.0 percent Over 90 percent of participants at 8 or 12 mg lost at least 10 percent of body weight Over 75 percent at 12 mg lost at least 20 percent Crucially, the weight loss curve had not yet plateaued at 48 weeks, suggesting longer treatment may produce even greater results

It also showed significant improvement in skin tone evenness at four and eight weeks, and in elasticity at four weeks